Proclaim: A phase III study of pemetrexed, cisplatin, and radiation therapy followed by consolidation pemetrexed versus etoposide, cisplatin, and radiation therapy followed by consolidation cytotoxic chemotherapy of choice in locally advanced stage III non-small-cell lung cancer of other than predominantly squamous cell histology

Everett E. Vokes; Suresh Senan; Joseph A. Treat; Neill A. Iscoe

doi:10.3816/CLC.2009.n.027

Proclaim: A phase III study of pemetrexed, cisplatin, and radiation therapy followed by consolidation pemetrexed versus etoposide, cisplatin, and radiation therapy followed by consolidation cytotoxic chemotherapy of choice in locally advanced stage III non-small-cell lung cancer of other than predominantly squamous cell histology

Everett E. Vokes, Suresh Senan, Joseph A. Treat, Neill A. Iscoe

Research output: Contribution to journal › Article › peer-review

50 Scopus citations

Abstract

This clinical trial summary provides the background and rationale for a randomized trial examining the benefits of pemetrexed/ cisplatin chemotherapy combined with radiation followed by consolidation pemetrexed in patients with stage IIIA/B non-small-cell lung cancer. The rationale for the selection of the control arm is provided, and study design limitations are discussed. The primary outcome is surviva, and secondary outcomes include progression-free survival, toxicities, and 1-, 2-, and 3-year survival rates Radiation quality control is a key component of the trial.

Original language	English
Pages (from-to)	193-198
Number of pages	6
Journal	Clinical Lung Cancer
Volume	10
Issue number	3
DOIs	https://doi.org/10.3816/CLC.2009.n.027
State	Published - 2009

Keywords

Concurrent chemoradiation therapy
Involved-field radiation
Platinum doublets
Randomized tr

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3816/CLC.2009.n.027

Fingerprint

Dive into the research topics of 'Proclaim: A phase III study of pemetrexed, cisplatin, and radiation therapy followed by consolidation pemetrexed versus etoposide, cisplatin, and radiation therapy followed by consolidation cytotoxic chemotherapy of choice in locally advanced stage III non-small-cell lung cancer of other than predominantly squamous cell histology'. Together they form a unique fingerprint.

Cite this

Vokes, E. E., Senan, S., Treat, J. A., & Iscoe, N. A. (2009). Proclaim: A phase III study of pemetrexed, cisplatin, and radiation therapy followed by consolidation pemetrexed versus etoposide, cisplatin, and radiation therapy followed by consolidation cytotoxic chemotherapy of choice in locally advanced stage III non-small-cell lung cancer of other than predominantly squamous cell histology. Clinical Lung Cancer, 10(3), 193-198. https://doi.org/10.3816/CLC.2009.n.027

Vokes, Everett E. ; Senan, Suresh ; Treat, Joseph A. et al. / Proclaim : A phase III study of pemetrexed, cisplatin, and radiation therapy followed by consolidation pemetrexed versus etoposide, cisplatin, and radiation therapy followed by consolidation cytotoxic chemotherapy of choice in locally advanced stage III non-small-cell lung cancer of other than predominantly squamous cell histology. In: Clinical Lung Cancer. 2009 ; Vol. 10, No. 3. pp. 193-198.

@article{b295c4fd11a64964a5a9f7650a4d937b,

title = "Proclaim: A phase III study of pemetrexed, cisplatin, and radiation therapy followed by consolidation pemetrexed versus etoposide, cisplatin, and radiation therapy followed by consolidation cytotoxic chemotherapy of choice in locally advanced stage III non-small-cell lung cancer of other than predominantly squamous cell histology",

abstract = "This clinical trial summary provides the background and rationale for a randomized trial examining the benefits of pemetrexed/ cisplatin chemotherapy combined with radiation followed by consolidation pemetrexed in patients with stage IIIA/B non-small-cell lung cancer. The rationale for the selection of the control arm is provided, and study design limitations are discussed. The primary outcome is surviva, and secondary outcomes include progression-free survival, toxicities, and 1-, 2-, and 3-year survival rates Radiation quality control is a key component of the trial.",

keywords = "Concurrent chemoradiation therapy, Involved-field radiation, Platinum doublets, Randomized tr",

author = "Vokes, {Everett E.} and Suresh Senan and Treat, {Joseph A.} and Iscoe, {Neill A.}",

year = "2009",

doi = "10.3816/CLC.2009.n.027",

language = "English",

volume = "10",

pages = "193--198",

journal = "Clinical Lung Cancer",

issn = "1525-7304",

publisher = "Elsevier Inc.",

number = "3",

}

Vokes, EE, Senan, S, Treat, JA & Iscoe, NA 2009, 'Proclaim: A phase III study of pemetrexed, cisplatin, and radiation therapy followed by consolidation pemetrexed versus etoposide, cisplatin, and radiation therapy followed by consolidation cytotoxic chemotherapy of choice in locally advanced stage III non-small-cell lung cancer of other than predominantly squamous cell histology', Clinical Lung Cancer, vol. 10, no. 3, pp. 193-198. https://doi.org/10.3816/CLC.2009.n.027

Proclaim: A phase III study of pemetrexed, cisplatin, and radiation therapy followed by consolidation pemetrexed versus etoposide, cisplatin, and radiation therapy followed by consolidation cytotoxic chemotherapy of choice in locally advanced stage III non-small-cell lung cancer of other than predominantly squamous cell histology. / Vokes, Everett E.; Senan, Suresh; Treat, Joseph A. et al.
In: Clinical Lung Cancer, Vol. 10, No. 3, 2009, p. 193-198.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Proclaim

T2 - A phase III study of pemetrexed, cisplatin, and radiation therapy followed by consolidation pemetrexed versus etoposide, cisplatin, and radiation therapy followed by consolidation cytotoxic chemotherapy of choice in locally advanced stage III non-small-cell lung cancer of other than predominantly squamous cell histology

AU - Vokes, Everett E.

AU - Senan, Suresh

AU - Treat, Joseph A.

AU - Iscoe, Neill A.

PY - 2009

Y1 - 2009

N2 - This clinical trial summary provides the background and rationale for a randomized trial examining the benefits of pemetrexed/ cisplatin chemotherapy combined with radiation followed by consolidation pemetrexed in patients with stage IIIA/B non-small-cell lung cancer. The rationale for the selection of the control arm is provided, and study design limitations are discussed. The primary outcome is surviva, and secondary outcomes include progression-free survival, toxicities, and 1-, 2-, and 3-year survival rates Radiation quality control is a key component of the trial.

AB - This clinical trial summary provides the background and rationale for a randomized trial examining the benefits of pemetrexed/ cisplatin chemotherapy combined with radiation followed by consolidation pemetrexed in patients with stage IIIA/B non-small-cell lung cancer. The rationale for the selection of the control arm is provided, and study design limitations are discussed. The primary outcome is surviva, and secondary outcomes include progression-free survival, toxicities, and 1-, 2-, and 3-year survival rates Radiation quality control is a key component of the trial.

KW - Concurrent chemoradiation therapy

KW - Involved-field radiation

KW - Platinum doublets

KW - Randomized tr

UR - http://www.scopus.com/inward/record.url?scp=67649405034&partnerID=8YFLogxK

U2 - 10.3816/CLC.2009.n.027

DO - 10.3816/CLC.2009.n.027

M3 - Article

C2 - 19443340

AN - SCOPUS:67649405034

SN - 1525-7304

VL - 10

SP - 193

EP - 198

JO - Clinical Lung Cancer

JF - Clinical Lung Cancer

IS - 3

ER -